Ophthalmic Business News

In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, AGTC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology.

Pierre Bertrand has been appointed as CEO of Neurolens, effective immediately, with current CEO and founder Davis Corley stepping into the role of executive chairman of the board of directors, according to a company press release.

Glaukos and Ivantis have entered into a settlement agreement to terminate a patent infringement lawsuit concerning the Hydrus microstent, according to company press releases.

AbbVie and Regenxbio have entered into a partnership to develop and commercialize RGX-314, an investigational gene therapy, for the treatment of retinal diseases, according to a press release.

Median payments made to male ophthalmologists in Ontario, Canada, in 2018 were higher than the median payments made to female ophthalmologists, according to a report.

In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more.

In this Healio Video Perspective, Jeannette Bankes, president and general manager, global surgical franchise for Alcon, discusses the return to in-person meetings and outlines some of the company’s highlights from the ASCRS meeting.

Alcon reported $2.1 billion in worldwide sales in the second quarter of 2021, an increase of 75% on a reported basis compared with the same period of 2020, according to a press release.

Visus Therapeutics has entered into worldwide exclusive licensing agreements with Cella Therapeutics and DelSiTech, according to a press release.

The American Academy of Ophthalmology will require all in-person attendees to be vaccinated against COVID-19 for its annual meeting in New Orleans in November, according to AAO guidance.